{"id":526452,"date":"2021-01-15T13:24:01","date_gmt":"2021-01-15T13:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=526452"},"modified":"2021-01-15T13:24:01","modified_gmt":"2021-01-15T13:24:01","slug":"antibodymediated-rejection-market-analysis-leading-companies-emerging-therapies-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/antibodymediated-rejection-market-analysis-leading-companies-emerging-therapies-and-epidemiology-forecast_526452.html","title":{"rendered":"Antibody-Mediated Rejection Market Analysis, Leading Companies, Emerging Therapies and Epidemiology Forecast"},"content":{"rendered":"
\"Antibody-Mediated<\/a><\/p>\n
\n
Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Antibody-Mediated Rejection Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Antibody-Mediated Rejection, historical and forecasted epidemiology as well as the Antibody-Mediated Rejection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Antibody-mediated rejection (AMR)<\/strong>—or humoral rejection—after renal transplantation is a devastating event that inevitably led to allograft loss. AMR poses a significant and continued challenge for long term graft survival in kidney transplantation. Allograft rejection is a complex process that involves the interplay of different cellular and molecular pathways that cause a broad range of allograft injuries (acute tubular injury, glomerulitis, capillaritis, and fibrinoid necrosis).<\/p>\n

Treatment of AMR<\/strong> is often initiated in situations of diffuse C4d positivity with allograft dysfunction even in the absence of DSA or histological evidence of AMR. The inability to measure DSAs in these cases may be related to the presence of non-anti-HLA antibodies, to antigen not present on the single-bead assays, or to the possibility that the DSAs may be completely absorbed onto the allograft.<\/p>\n

 Get FREE sample copy at: 
<\/strong>https:\/\/www.delveinsight.com\/sample-request\/antibody-mediated-rejection-market<\/strong><\/a><\/p>\n

The Antibody-Mediated Rejection market report<\/strong> also covers emerging drugs, current treatment practices, Antibody-Mediated Rejection market share of the individual therapies, current and forecasted Antibody-Mediated Rejection Market Size from 2017 to 2030 segmented by seven major markets. <\/p>\n

The report provides a detailed current Antibody-Mediated Rejection treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. <\/p>\n

\"Antibody-Mediated<\/a><\/p>\n

 <\/p>\n

Antibody-Mediated Rejection Market Key Facts<\/strong><\/p>\n

As per the study conducted by Valenzuela et al. (2017), the incidence tends to be higher (up to 40%) in pediatric and medication-non-adherence adult transplant patients, with the latter constituting nearly two-thirds of adult transplant patients by 12 years after transplantation. AMR incidence among pre-sensitized patients<\/strong> is more than 20%.<\/p>\n

According to the study conducted by Puttarajappa et al. (2012), acute AMR<\/strong> occurs in about 5–7% of all kidney transplants and is responsible for 20–48% of acute rejection episodes among pre-sensitized positive crossmatch patients.<\/p>\n

As per the study conducted by Calp-Inal et al. (2016), the incidence of acute and chronic AMR<\/strong> was 45% and 36% in patients with C1q+DSA. The study indicated that the presence of C1q+ DSA was associated with acute and chronic AMR.<\/p>\n

 Key Benefits of Antibody-Mediated Rejection Market Report<\/strong><\/p>\n